Navigation Links
Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Date:8/24/2007

SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that Steve Worland, Ph.D. has been promoted to the position of President and Chief Executive Officer, replacing Lawrence C. Fritz, Ph.D. who plans to pursue other opportunities. Dr. Worland has also been appointed as a member of the Company's Board of Directors.

Dr. Worland joined Anadys in March 2001 as Chief Scientific Officer and most recently served as President, Pharmaceuticals. Prior to joining the Company, Dr. Worland was Vice President, Head of Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company and was also a Vice President at Warner-Lambert prior to the acquisition by Pfizer.

"We are pleased to appoint Steve as President and CEO," said George A. Scangos, Ph.D., Chairman of the Board. "Steve has been intimately involved in building Anadys since its early days, knows the ANA773 and ANA598 programs in detail, and has the right skills and experience to lead the Company as it pursues the development of these two programs. The current focus for Anadys is to aggressively advance these projects, focus on execution and meet our objectives. Steve, who has evolved into a business and scientific leader, is perfectly positioned to lead the Company in pursuit of these goals. We remain on track to file an IND for ANA773 this year and an IND for ANA598 in the first half of 2008."

"I would like to thank Larry for his service and contributions to Anadys and wish him well with his future endeavors," added Dr. Scangos. "Larry has p
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Sharon Ethanol appoints operations director
4. Kyron appoints former AMA chairman to board
5. Brady appoints GE efficiency expert as CTO
6. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
7. Johnson Controls appoints Roell to head EOC
8. SecurePipe appoints two senior execs
9. Milwaukees PointOne appoints new president and CEO
10. Third Wave appoints new chairman
11. Midwest Venture Summit disappoints; Cato grades Midwest governors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)..., GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCal...d its financial results for the third quarter ende...f $3.6 million ($0.04 per share) for the three mon...s of $6.8 million ($0.08 per share) in the compara...tember 30, 2009, GenVec,s net loss was $14.1 milli...
(Date:11/5/2009)..., RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-Fir... leading supplier of innovative products for proce... results for the first quarter of fiscal 2010. ,...ompany reported revenues of $5.2 million, a 15 per... first quarter a year ago. The Company said the ke...
(Date:11/5/2009)..., SUNNYVALE, Calif., Nov. 5 /PRNewswire-FirstCal...t its executives will be speaking at the following...rticipate via webcast. , , Credit ... Thursday, 12 November, 2009 at 10 a.m. Mo...stor Program, London, England, Tue...
(Date:11/5/2009)..., AUSTIN, Texas, Nov. 5 SpineSmi...enOsteo, Inc. to co-develop a unique scaffold that... Following evaluation of several commercial produc...ment, the company believes the GenOsteo scaffold r...that creates a unique and ideal environment for th...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
...eremony Also Celebrates Opening of Hollings Expand...cal University of,South Carolina,s Hollings Cancer...tine Healing Garden. The healing garden, designed ...ft from Edwin S. Pearlstine, Jr., in memory,of his...died of cancer in,1997., "Edwin and Barbara Pearl...
...laine & Kenneth Langone contribute unrestricted $2...Center,( http://www.med.nyu.edu/ ) today announced...G. Langone Medical Center, in honor of the chairma...estricted $200 million gift is the,largest in the ...ade by Robert I. Grossman, M.D.,( http://www.med.n...
...UEBEC CITY, April 16 /PRNewswire-FirstCall/ - Vict...isclosed initial results from the ongoing,human cl...stem (CLS) used,in the Neurostep(TM) for the treat...y to a central nervous system lesion. According to...e demonstrated that the Neurostep(TM) is,capable o...
Other Biology Technology:MUSC's Hollings Cancer Center Dedicates Edwin and Barbara Pearlstine Healing Garden Endowed with $1 Million Gift from Edwin S. Pearlstine, Jr. 2NYU Medical Center Changes Name to Honor Chairman of Board & Wife 2NYU Medical Center Changes Name to Honor Chairman of Board & Wife 3NYU Medical Center Changes Name to Honor Chairman of Board & Wife 4NYU Medical Center Changes Name to Honor Chairman of Board & Wife 5Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system 2
(Date:11/4/2009).... 4 GenVault Corporation (Carlsbad....D., has joined its Board of Directors. Dr. Brody...Institute, is an acclaimed physician-scientist and...titute, Dr. Brody served as president of The Johns...al Academy of Engineering and the Institute of Med...
(Date:11/3/2009)...e ultimate loner of the ocean, cruising thousands ...hers has discovered that the sharks have maintaine... tens of thousands of years the white sharks in th...lves into a population genetically distinct from s...e a large, highly mobile species," said Salvador J...
(Date:11/3/2009)..., Ind. - Chief executives in 35 of the top Fortune...eir "ideal salaries" in 2008, according to a new t...niversity researcher to determine fair CEO compens...corporate governance issues of the day is how to d...Venkatasubramanian, a professor of chemical engine...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10 Q Filing 13726 1Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10 Q Filing 13726 2Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10 Q Filing 13726 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 4909 1Boston Scientific Announces Schedule for European Society of Cardiology Congress 4909 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 4909 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 4909 4Boston Scientific Announces Schedule for European Society of Cardiology Congress 4909 5Boston Scientific Announces Schedule for European Society of Cardiology Congress 4909 6Steady Improvements Seen for Young Blood Cancer Patients 55572 1Steady Improvements Seen for Young Blood Cancer Patients 55572 2
... University of Pennsylvania School of Medicine hav...te by re-awakening genes once active only in devel...evidence for the first time that, like other anima... power to regenerate. These findings are published...standing of this process could lead to novel treat...
... of its kind to evaluate how smoking restrictions ... researchers at the Mailman School of Public Healt...l household and total workplace smoking ban are ov...er health than those without smoking bans. The st...e and work in New York City. , The study confirms...
...smile, Dad,s eyes and Grandpa,s laugh, you might w...ealogic fabric of the ol, family tree. , Scie...cultural Research and Extension at Lubbock are stu...reason. , "Cotton genetic diversity has n...Texas Agricultural Experiment Station cotton breed...
Other Biology News:First demonstration of new hair follicle generation in an animal model 2Better health twice as likely for nonsmokers who live and work with smoking restrictions 2Scientists seek useful traits in wild cottons 2Scientists seek useful traits in wild cottons 3Scientists seek useful traits in wild cottons 4
Mouse Anti-Human Relaxin-2, pro- Monoclonal Antibody, Unconjugated, Clone fred from Immundiagnostik
Rabbit Anti-Chicken IgY, IgG F(ab')2 fragment Antibody, Rhodamine Conjugated from Biomeda Corporation
Goat Anti-Human Presenilin 2 Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-TWIK-2 (Kcnk6, TOSS) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: